Effects of other therapeutic agents on PMF CD34+ cells
| Treatment . | No. of total cells (×105) . | No. of CD34+ cells (×105) . | No. of CD34+CXCR4+ cells (×103) . | No. of CFU-GM . | No. of BFU-E . | No. of CFU-Mixed . |
|---|---|---|---|---|---|---|
| Primary | 1.0 ± 0.1 | 1.0 ± 0.0 | 0.9 ± 0.3 | 7392 ± 2226 | 2100 ± 1152 | 360 ± 162 |
| Cytokines alone | 2.8 ± 0.7 | 0.6 ± 0.3 | 3.6 ± 1.9 | 9032 ± 2880 | 4000 ± 1326 | 732 ± 458 |
| Cytokines + JAK inhibitor 1 (100nM) | 2.2 ± 0.7 | 0.6 ± 0.3 | 3.7 ± 2.5 | 7002 ± 1477 | 3203 ± 1212 | 360 ± 360 |
| Cytokines + AZ1480 (100nM) | 1.7 ± 0.4* | 0.4 ± 0.2 | 1.0 ± 0.4 | 6712 ± 990 | 3184 ± 1250 | 720 ± 120 |
| Cytokines + Hydroxyurea (50μM) | 0.7 ± 0.2* | 0.1 ± 0.0 | 0.6 ± 0.2 | 2617 ± 1140 | 770 ± 450 | 104 ± 104 |
| Cytokines + Peg-IFN-α2a (125 U) | 1.7 ± 0.5* | 0.4 ± 0.2 | 1.6 ± 0.6 | 6885 ± 2187 | 1963 ± 882 | 896 ± 571 |
| Treatment . | No. of total cells (×105) . | No. of CD34+ cells (×105) . | No. of CD34+CXCR4+ cells (×103) . | No. of CFU-GM . | No. of BFU-E . | No. of CFU-Mixed . |
|---|---|---|---|---|---|---|
| Primary | 1.0 ± 0.1 | 1.0 ± 0.0 | 0.9 ± 0.3 | 7392 ± 2226 | 2100 ± 1152 | 360 ± 162 |
| Cytokines alone | 2.8 ± 0.7 | 0.6 ± 0.3 | 3.6 ± 1.9 | 9032 ± 2880 | 4000 ± 1326 | 732 ± 458 |
| Cytokines + JAK inhibitor 1 (100nM) | 2.2 ± 0.7 | 0.6 ± 0.3 | 3.7 ± 2.5 | 7002 ± 1477 | 3203 ± 1212 | 360 ± 360 |
| Cytokines + AZ1480 (100nM) | 1.7 ± 0.4* | 0.4 ± 0.2 | 1.0 ± 0.4 | 6712 ± 990 | 3184 ± 1250 | 720 ± 120 |
| Cytokines + Hydroxyurea (50μM) | 0.7 ± 0.2* | 0.1 ± 0.0 | 0.6 ± 0.2 | 2617 ± 1140 | 770 ± 450 | 104 ± 104 |
| Cytokines + Peg-IFN-α2a (125 U) | 1.7 ± 0.5* | 0.4 ± 0.2 | 1.6 ± 0.6 | 6885 ± 2187 | 1963 ± 882 | 896 ± 571 |
PMF CD34+ cells (1 × 105) were treated with cytokines alone or cytokines plus various agents.
P < .05 vs PMF CD34+ cells treated with cytokines alone; n = 5.